Insulet (NASDAQ:PODD) Upgraded at UBS Group

Posted by Stanley Muller on Jul 29th, 2026

Insulet (NASDAQ:PODD – Get Free Report) was upgraded by equities researchers at UBS Group to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.

A number of other analysts have also issued reports on the stock. Sanford C. Bernstein cut their price target on shares of Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Royal Bank Of Canada cut their target price on shares of Insulet from $280.00 to $245.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Weiss Ratings cut shares of Insulet from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, June 24th. William Blair began coverage on shares of Insulet in a research note on Wednesday, May 20th. They issued an “outperform” rating for the company. Finally, Jefferies Financial Group reduced their price objective on Insulet from $400.00 to $360.00 in a research note on Thursday, May 7th. Twenty-one investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $233.38.

Get Our Latest Report on Insulet

Insulet Trading Up 1.5%

PODD opened at $167.47 on Tuesday. Insulet has a 52 week low of $138.79 and a 52 week high of $354.88. The business has a fifty day simple moving average of $154.59 and a 200-day simple moving average of $200.20. The firm has a market cap of $11.60 billion, a P/E ratio of 38.95, a P/E/G ratio of 1.15 and a beta of 1.11. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. During the same quarter in the previous year, the business earned $1.02 EPS. The company’s quarterly revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities analysts expect that Insulet will post 6.45 earnings per share for the current year.

Insider Activity at Insulet

In other news, Director Timothy C. Stonesifer acquired 2,790 shares of Insulet stock in a transaction dated Wednesday, June 3rd. The shares were acquired at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the acquisition, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.36% of the company’s stock.

Hedge Funds Weigh In On Insulet

Several large investors have recently bought and sold shares of the business. Glenmede Investment Management LP raised its stake in Insulet by 1.6% in the third quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after buying an additional 35 shares in the last quarter. Curi Capital LLC boosted its position in shares of Insulet by 0.8% during the 2nd quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after acquiring an additional 36 shares in the last quarter. Great Lakes Advisors LLC increased its holdings in shares of Insulet by 1.5% in the 4th quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier’s stock valued at $791,000 after acquiring an additional 40 shares during the last quarter. Camarda Financial Advisors LLC increased its holdings in shares of Insulet by 0.5% in the 2nd quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after acquiring an additional 40 shares during the last quarter. Finally, Larson Financial Group LLC raised its position in shares of Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 47 shares in the last quarter.

More Insulet News

Here are the key news stories impacting Insulet this week:

Neutral Sentiment: Several law firms reminded investors that August 31, 2026 is the deadline to seek appointment as lead plaintiff for purchasers of Insulet securities during periods generally spanning February 21, 2025, through May 26, 2026. These notices are procedural and do not establish that Insulet committed wrongdoing. Rosen Law Firm investor notice
Negative Sentiment: Pomerantz said a class action was filed in federal court against Insulet and certain officers under federal securities laws, seeking damages for investors who acquired the company’s securities during the alleged class period. Pomerantz class action announcement
Negative Sentiment: The complaints allege that Insulet misrepresented the safety of its Omnipod products and failed to disclose manufacturing deficiencies that were allegedly revealed through two medical-device corrections. One investor notice also highlighted former executive Eric Benjamin’s reported sale of approximately $3.7 million in Insulet stock before those disclosures. SueWallSt shareholder alert
Negative Sentiment: Law firms said the alleged disclosures contributed to a stock decline of more than 6%, increasing concerns about product safety, regulatory exposure, litigation costs, management credibility, and potential damages. The allegations remain unproven, and the ultimate financial impact is uncertain. Bleichmar Fonti & Auld class reminder

About Insulet

(Get Free Report)

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.